A recently published study demonstrates that sarilumab improves patient-reported outcomes in patients with rheumatoid arthritis who did not achieve adequate response with, or who were intolerant to, anti-tumor necrosis factor (anti-TNF) agents.
A recently published study demonstrates that sarilumab improves patient-reported outcomes (PROs) in patients with rheumatoid arthritis (RA) who did not achieve adequate response with, or who were intolerant to, anti-tumor necrosis factor (anti-TNF) agents.
Vibeke Strand, MD, and her coauthors, in a study sponsored by Sanofi and Regeneron, evaluated the effects of the monoclonal antibody administered together with conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) based on PROs in the TARGET trial.
The authors note that PROs are important supplemental endpoints that can help in evaluating responses to treatment for RA. While clinical measures of RA, including the American College of Rheumatology (ACR) response criteria, include PROs, such measures rarely assess fatigue, ability to work, health-related quality of life, or health status.
In the TARGET trial, which included the assessment of PROs, 546 adults with moderate to severe RA who did not respond adequately to, or did not tolerate, anti-TNF treatments were randomized to receive placebo, 150 mg of sarilumab, or 200 mg of sarilumab every 2 weeks together with csDMARDs. The PROs addressed in the study included measures of pain, fatigue, function, participation, and health status. The methods used to assess these areas included:
Changes from baseline at weeks 12 and 24 were analyzed using a mixed model for repeated measures that tested the least square mean (LSM) changes from baseline, between each active treatment group and the placebo group, at weeks 12 and 24. Post hoc analyses included percentages of patients who reported improvements greater than or equal to minimum clinically important differences and scores greater than or equal to normative values.
Sarilumab in both doses, in combination with csDMARDs, resulted in greater improvements from baseline versus placebo together with csDMARDs:
Among patients who were employed outside the home:
The researchers concluded that, in patients for whom treatment with anti-TNF agents was inadequate or not tolerated, 150-mg and 200-mg doses of sarilumab, given together with csDMARDs, resulted in clinically meaningful patient-reported benefits in terms of pain, fatigue, function, participation, and health status at week 12 and week 24, and that mean changes from baseline translated into clinically meaningful benefits on an individual patient level.
Strand, during a recent Peer Exchange™ panel discussion at The Center for Biosimilars®, said, “In general, I think we’re learning a lot more about the biologic products, and that translates also into learning how we might have better precision medicine—how there might be individual variability and what the appropriate therapy is for a patient. We’re still just cracking that nut, but I think it’s one of the things to look forward to.”
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Study: Biosimilar Use, Dose Rounding Produce More Cost Savings Than Either Strategy Alone
November 18th 2023A retrospective study of New England patients receiving trastuzumab or bevacizumab found that combining dose rounding and biosimilar use resulted in greater cost savings than either strategy alone.
Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars
April 16th 2023What can practices do to prepare for all the biosimilars to treat rheumatoid arthritis (RA) coming down the pipeline? And how can they ensure that the lower-than-anticipated adoption rates for infliximab biosimilars are not repeated? Robert Zutaut, RPh, from McKesson Provider Solutions, tackles all this and more on this episode of Not So Different.
Panelists Deliberate Strategies to Enhance Biosimilar Integration in Managed Care Spaces
November 13th 2023At the recent Academy of Managed Care Pharmacy Nexus meeting, panelists discussed the impact of introducing biosimilars in new medical fields, emphasizing the need for more education and collaboration to ensure their smooth integration into health care systems.
Public Payer in Poland Saves €243 Million by Using Biosimilar TNF Inhibitors
November 11th 2023The use of biosimilars of tumor necrosis factor (TNF) inhibitors within Poland’s public payer saved over €243 million from 2013 to 2021, with about 68% of that coming from the rheumatic musculoskeletal diseases alone.